Stockscreener 앱 받기
36.81
5.72%
1.99
전일 마감가:
$34.82
열려 있는:
$35.785
하루 거래량:
1.99M
Relative Volume:
1.54
시가총액:
$3.96B
수익:
-
순이익/손실:
$-176.01M
주가수익비율:
-22.16
EPS:
-1.661
순현금흐름:
$-148.97M
1주 성능:
+8.49%
1개월 성능:
+16.05%
6개월 성능:
+74.04%
1년 성능:
+154.39%
1일 변동 폭
$35.39
$37.14
1주일 범위
$30.84
$37.14
52주 변동 폭
$12.15
$40.77
엣지와이즈 Stock (EWTX) Company Profile
명칭
Edgewise Therapeutics Inc
전화
720-262-7002
주소
1715 38TH ST, BOULDER
Compare EWTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
36.81 | 3.96B | 0 | -176.01M | -148.97M | -1.661 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
엣지와이즈 Stock (EWTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-25 | 개시 | Goldman | Neutral |
| 2025-07-30 | 개시 | Raymond James | Strong Buy |
| 2025-06-30 | 개시 | H.C. Wainwright | Buy |
| 2025-04-30 | 개시 | Guggenheim | Buy |
| 2025-04-02 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-01-22 | 개시 | Stifel | Hold |
| 2024-11-22 | 개시 | Evercore ISI | Outperform |
| 2024-03-07 | 개시 | Piper Sandler | Overweight |
| 2023-05-01 | 개시 | Truist | Buy |
| 2022-08-25 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-04-13 | 개시 | RBC Capital Mkts | Outperform |
| 2022-01-28 | 개시 | Goldman | Neutral |
모두보기
엣지와이즈 주식(EWTX)의 최신 뉴스
Edgewise Therapeutics Inc (EWTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Edgewise Therapeutics Inc (EWTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Edgewise Therapeutics Inc (EWTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Edgewise Therapeutics Inc (EWTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Edgewise Therapeutics Inc (EWTX) Institutional Confidence - TradingKey
Edgewise Therapeutics Inc (EWTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Edgewise Therapeutics (EWTX) director granted 16,377 stock options at $35.59 - Stock Titan
Edgewise Therapeutics (EWTX) director receives grant of 16,377 stock options - Stock Titan
Director at Edgewise (NASDAQ: EWTX) awarded 16,377 stock options - Stock Titan
Edgewise Therapeutics Inc (EWTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
EWTX Maintained by Goldman Sachs -- Price Target Raised to $32.0 - GuruFocus
Edgewise Therapeutics Inc (EWTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Edgewise shares slip despite positive Phase II HCM data for EDG-7500 - The Pharma Letter
Edgewise Therapeutics Inc (EWTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
RBC Raises Price Target on Edgewise Therapeutics to $59 From $48, Keeps Outperform, Speculative Risk - marketscreener.com
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic CardiomyopathySlideshow (NASDAQ:EWTX) 2026-06-17 - Seeking Alpha
Edgewise shares slip after heart-disease drug trial data disappoints investors - 1470 & 100.3 WMBD
Edgewise Therapeutics (NASDAQ: EWTX) grants director equity awards - Stock Titan
[Form 4] Edgewise Therapeutics, Inc. Insider Trading Activity - Stock Titan
Edgewise Edges Into Phase III With EDG-7500 - Citeline News & Insights
EWTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
EWTX: EDG-7500 showed strong efficacy and safety in HCM, enabling echo-independent dosing - TradingView
Edgewise Therapeutics Reports Improvements In Heart Drug Trial - Benzinga
Edgewise heart drug passes key trial test - BioPharma Dive
Edgewise heads to phase III with solid EDG-7500 data in HCM - BioWorld News
Edgewise Therapeutics (EWTX) Sees Significant Drop in Share Price - GuruFocus
Edgewise Therapeutics reports positive Phase 2 heart data - grafa.com
Edgewise reports phase 2 trial results for heart disease drug By Investing.com - Investing.com South Africa
Edgewise Therapeutics stock tumbles 25% on trial data By Investing.com - Investing.com Nigeria
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) - BioSpace
Edgewise Therapeutics (EWTX) Shares Plunge 25% After Trial Update - GuruFocus
Edgewise posts trial data for heart disease drug (EWTX:NASDAQ) - Seeking Alpha
SpaceX, Rackspace surge premarket; Edgewise Therapeutics, Huntsman fall - Investing.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Edgewise Therapeutics stock tumbles 25% on trial data - Investing.com
Edgewise Therapeutics Advances EDG-7500 to Phase 3 Following 'Positive' HCM Data - marketscreener.com
Edgewise reports phase 2 trial results for heart disease drug - Investing.com
(EWTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Number of shareholders of Edgewise Therapeutics, Inc. – NASDAQ:EWTX - TradingView
Edgewise Therapeutics, Inc. 2026 Annual Meeting Results and SEC Filing Details - Minichart
Edgewise Therapeutics Shareholders Back Board and Governance - TipRanks
Edgewise Therapeutics (EWTX) shareholders approve directors, KPMG and executive pay - Stock Titan
Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement - Seeking Alpha
Paradigm Biocapital Advisors LP's Edgewise Therapeutics Inc(EWTX) Holding History - GuruFocus
Liquidity Mapping Around (EWTX) Price Events - Stock Traders Daily
Edgewise Therapeutics Reports Inducement Grants As Permitted By Nasdaq Listing Rules - TradingView
Edgewise Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules - 富途牛牛
Guggenheim Reaffirms Their Buy Rating on Edgewise Therapeutics (EWTX) - The Globe and Mail
Servier to Acquire Edgewise's Muscular Dystrophy Drug in USD 2.65 Billion Deal - Medical Dialogues
Edgewise sells sevasemten for up to $2.65 billion - The Pharma Letter
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal - The Globe and Mail
엣지와이즈 (EWTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):